Study | Study location | Study design | PCa Cases (number) | Died from PCa (number) | Age (y) | Median follow-up (y) | Drugs studied | Treatment | Tumor stage | Confounders for adjustment | Quality score |
---|---|---|---|---|---|---|---|---|---|---|---|
Flahavan, 2014 [39] | Ireland | Cohort | 2,936 | 104 | 70.5 | 5.5 | Aspirin | PR, RT, ADT | I–III | 1–8 | 8 |
Grytli, 2014 [40] | Norway | Cohort | 3,561 | 1,010 | 76.3 | 3.3 | Aspirin | ADT | I–IV | 1, 2, 9–13 | 7 |
Cardwell, 2013 [41] | UK | Nested case–control | 6,339 | 1,184 | NR | 6.0 | Aspirin | PR, RT, ADT, EST | I–IV | 1, 4, 8, 13–17 | 7 |
Dhillon, 2012 [42] | USA | Cohort | 3,986 | 265 | 68.6 | 8.4 | Aspirin/NSAIDs/ NA-NSAIDs | PR, RT, EST | I–IIIab | 1, 2, 4, 6, 10, 18–29 | 7 |
Choe, 2012 [43] | USA | Cohort | 5,955 | 193 | 64.0 | 5.8 | Aspirin | RP, RT | I–IV | 1, 2, 9, 10, 29–31 | 8 |
Stock, 2008 [44] | Canada | Case–control | 1,619 | 453 | 67.2 | NR | NSAIDs | RP, RT | I–IV | 1, 2, 9, 21 | 7 |
Ratnasinghe, 2004 [45] | USA | Cohort | NR | 121 | 25–74 | NR | Aspirin | NR | NR | 1, 4, 19, 21, 32–33 | 6 |
Lipworth, 2004 [46] | Denmark | Cohort | NR | 296 | 48.4 | 4.3 | NA-NSAIDs | NR | NR | 1, 33 | 5 |